DGAP-News: ADL Bionatur Solutions / Key word(s): Alliance
26.09.2018 / 08:00
The issuer is solely responsible for the content of this announcement.
Fermentalg and ADL BioPharma announce a majormanufacturing alliance to produce Omega 3 food supplements
Libourne, France, and Madrid, Spain – 26 September 2018 – Fermentalg (Euronext – FALG), a French market leader in microalgae for human nutrition and health, and ADL BioPharma (ADL Bionatur group, Madrid – ADL), a major European player for the development and production of fermentation process-based projects, today announced the signing of a long-term manufacturing contract to produce Fermentalg’s algal oil DHA ORIGINS(R).
ADL BioPharma and Fermentalg plan to complete the validation and technology transfer phase before the end of 2018. ADL then will dedicate a part of its fermentation capacity to Fermentalg productions, allowing it to supply hundreds of tons to the growing DHA ORIGINS 550(R) market.
Philippe Lavielle, CEO of Fermentalg, says: “This long-term contract, following the signature of a major commercial partnership, secures our supply of our high value DHA ORIGINS 550(R), the algal DHA with the highest natural concentration on the market. ADL BioPharma’s scale, extensive experience and capabilities in fermentation and extraction technologies will support our commitment to become one of the world’s largest producers of algal DHA.”
Pilar de la Huerta, CEO of ADL BioPharma, says: “This is the fourth long-term manufacturing contract that we have signed in the last ten months, securing more than 85% of our fermentation capacity for the next several years and demonstrating the market need for state-of-the-art industrial fermentation sites. Fermentalg is a leader in the global premium algal Omega-3 market for human nutrition, and we are delighted to be their partner for a key part of their value chain.”
ADL BioPharma, 100% subsidiary of ADL Bionatur group, is a European leader in biotech contract manufacturing fermentation. The company owns and operates one of the most advanced industrial biotechnology plants in Southern Europe with a current fermentation capacity of 2,400 m3. Combined with its large scale of operations and experience in the field, ADL Biopharma offers the highest quality standards, including European and US FDA certifications for the pharmaceutical, cosmetics and food industries.
Fermentalg shares are listed on Euronext in Paris (FR0011271600 – FALG).
About ADL BioPharma:
ADL Biopharma is part of ADL Bionatur Solutions, a European leader in biotech health sector focused on high value fermentation products. ADL Bionatur Solutions, controlled by the investment fund Black Toro Capital (BTC) with 73% of the capital, resulted from the integration between ADL Biopharma and Bionaturis. Integration involved combining in a single entity the specialization in R&D in health products and services, with industrial production by fermentation and manufacturing capacity. ADL Bionatur Solutions is listed on the Spanish Alternative Market MaB (Ticker ADL) since May 2018. The company provides qualified employment to more than 250 people and its markets are mainly located in Europe and the United States. For more information, visit: www.adlbionatur.com
Contact details (Journalists and Investors)
26.09.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.